| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol/patient disposition |
|---|---|---|---|---|---|
|
RAINBOW Ranibizumab Versus Laser for the Treatment of Very Low Birthweight Infants With Retinopathy of Prematurity (RAINBOW): An Open-Label Randomised Controlled Trial |
214 |
Novartis (NCT02375971) |
2017 | Stahl A, Lepore D, Fielder A, et al. Ranibizumab Versus Laser for the Treatment of Very Low Birthweight Infants With Retinopathy of Prematurity (RAINBOW): An Open-Label Randomised Controlled Trial. Lancet. 2019;394:1551-1559. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)31344-3/fulltext |
|